Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Monitoring response to therapy in patients with previously diagnosed Sezary syndrome or mycosis fungoides
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
FCIMS | Flow Cytometry Interp, 9-15 Markers | No | No |
FCINS | Flow Cytometry Interp,16 or greater | No | No |
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
FIRST | Flow Cytometry, Cell Surface, First | No | Yes |
ADD1 | Flow Cytometry, Cell Surface, Addl | No | Yes |
Sezary panel is ordered in cases with previously diagnosed Sezary syndrome or cutaneous T-cell lymphoma (CTCL) with peripheral blood involvement. For cases without a previously confirmed diagnosis or previously performed immunophenotyping at our laboratory, the ordered test will be changed to SZDIA / Sezary Diagnostic Flow Cytometry, Blood, which includes a triage panel to exclude a B-cell lymphoproliferative disorder and a Sezary panel.
The panel is charged based on number of markers tested (FIRST for first marker, ADD1 for each additional marker). In addition, reflex testing may occur to fully characterize a disease state or clarify any abnormalities from the screening test. Reflex tests will be performed at an additional charge for each marker tested (ADD1 if applicable).
Immunophenotyping